Therefore, cetuximab treatment after anti-PD-1 treatment for R/M HNSCC, including rechallenge of cetuximab, might be modulated via combination treatment involving cetuximab and ipilimumab, may expect high response rates and improve survival for patients with HPD of HNSCC (Fig. 5). Here, PDCD1 is linked to head and neck squamous cell carcinoma.